Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cemiplimab + INO-5401 + INO-9012 + Temozolomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cemiplimab||Libtayo||REGN2810|SAR439684||Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 101||Libtayo (cemiplimab) is a human antibody that targets PD-1 (PDCD1) and prevents interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006). Libtayo (cemiplimab) is FDA approved for use in patients with cutaneous squamous cell carcinoma, who are not not eligible for curative surgery or radiation, in patients with locally advanced or metastatic basal cell carcinoma who have received or are not eligible for a hedgehog pathway inhibitor, as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression (TPS>=50%) and no EGFR, ALK, or ROS1 aberrations, and in combination with platinum-based chemotherapy as first-line treatment for patients with NSCLC without EGFR, ALK, or ROS1 alterations (FDA.gov).|
|INO-5401||INO5401|INO 5401||INO-5401 is a synthetic DNA immunotherapy that delivers plasmids to express three tumor associated antigens (WT1, PSMA (FOLH1), and TERT), which stimulates the immune system to attack cells expressing these antigens (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT114).|
|INO-9012||INO9012|INO 9012||INO-9012 is a plasmid encoding IL-12 protein subunits, p35 and p40, which may increase anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT114, PMID: 32208168).|
|Temozolomide||Temodar||Methazolastone|TMZ||Chemotherapy - Alkylating 16||Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03491683||Phase Ib/II||Cemiplimab + INO-5401 + INO-9012 + Temozolomide||INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)||Active, not recruiting||USA||0|